Federal Register / Vol. 62, No. 234 / Friday, December 5, 1997 / Notices 64391

For lots with total weight greater than

150,000 pounds, a sample will be selected

from 20 percent of the containers in the lot

and consist of 25 lb of shelled nuts or 50 lb

of in-shell nuts for each multiple of 75,000

lb (e.g., 150,000 to 225,000 lb requires a 3-

fold sample of 75 lb shelled or 150 lb of inshell nuts).

2. Perform aflatoxin assay.

(a) In-Shell Lots.

The entire sample of shells and kernels

will be ground in a vertical cutter mixer. A

well-mixed portion of the ground composite

will be assayed chemically for total

aflatoxins, using either of the two methods

for aflatoxin assay in pistachios described in

the book of Official Methods of Analysis of

AOAC International, 16th ed., Vol. II, Sec.

49.2.23. The aflatoxin level will be calculated

on a kernel weight basis.

(b) Shelled Lots

The entire sample shall be ground,

including those kernels which have an

obvious inedible appearance. A well-mixed

portion of the ground composite will be

assayed as in paragraph 2.(a) above.

3. Report Results

(a) A separate analysis certificate will be

issued for each lot. Appropriate

identification marks will be shown on

each certificate so that the report can be

related to the specific lot sampled.

(b) Provide appropriate FDA District Office

the results of aflatoxin analysis for lots

that may be subject to action under the

Food, Drug, and Cosmetic Act and

analysis certificate on any lot upon

request.

FDA intends to:

1. Notify AMS of the criteria FDA will use

concerning total aflatoxins levels in lots

to determine whether they may be

subject to action under the Food, Drug,

and Cosmetic Act.

2. Review results of aflatoxin analysis for

lots provided by AMS to determine

whether they may be subject to action

under the Food, Drug, and Cosmetic Act.

AMS and FDA mutually agree to:

1. Designate a person to serve as a central

contact to whom communications

dealing with this agreement or matters

affected thereby may be first referred for

attention.

For the Food and Drug Administration:

Director, Division of Programs and

Enforcement Policy, HFS–305 (currently

Terry C. Troxell, Ph.D.) Office of Plant and

Dairy Foods and Beverages, Center for Food

Safety and Applied Nutrition 200 C. Street

S.W. Washington, D.C. 20204 Telephone:

202–205–5321

For the Agricultural Marketing Service:

Director, Science and Technology Division

(currently William J. Franks, Jr.) USDA, AMS

14th & Independence Avenue, S.W.

Washington, D.C. 20090–6456, Telephone:

202–720–6496.

2. Maintain close working relations with

each other, both in headquarters as well

as in the field.

3. Work with industry toward greater

efficiency in connection with

improvement of the testing program.

BASIS OF COOPERATION—This

Memorandum of Understanding defines in

general terms the basis on which the parties

concerned will cooperate, and does not

constitute a financial obligation to serve as a

basis for expenditures. Each party will

handle and expend its own funds. Any and

all expenditures from Federal funds in the

Department of Agriculture made in

conformity with the plans outlined in the

Memorandum of Understanding must be in

accord with Department rules and

regulations and in each instance based upon

appropriate finance papers. Expenditures

made by FDA will be in accord with its rules

and regulations.

Nothing in this agreement modifies other

existing agreements, nor does it preclude

entering into separate agreements setting

forth procedures for special programs that

can be handled more efficiently and

expeditiously by such special agreement.

The responsibilities assumed by the

cooperating parties under this Memorandum

of Understanding are contingent upon funds

being available from which expenditures

legally may be made.

DURATION—This agreement will continue

in force indefinitely. It may be amended or

terminated by mutual consent of the parties

in writing. It may be terminated by either

party upon 30 days’ notice in writing to the

other party.

This agreement is hereby approved for the

Agricultural Marketing Service.

Done at Washington, D.C. on October 1, 1997,

Barbara A. Chaffey,

Deputy Administrator, Marketing Programs

Agricultural Marketing Service.

This agreement is hereby approved for the

Food and Drug Administration:

Done at Washington, D.C. on October 1, 1997,

Ronald G. Chesemore,

Associate Commissioner for Regulatory

Affairs.

[FR Doc. 97–31809 Filed 12–4–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 96N–0496]

Agency Information Collection

Activities; Announcement of OMB

Approval

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that a collection of information entitled

‘‘Reporting and Recordkeeping

Requirements for Manufacturers and

Distributors of Electronic Products’’ has

been approved by the Office of

Management and Budget (OMB) under

the Paperwork Reduction Act of 1995

(the PRA).

FOR FURTHER INFORMATION CONTACT:

Margaret R. Schlosburg, Office of

Information Resources Management

(HFA–250), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the

Federal Register of August 28, 1997 (62

FR 45665), the agency announced that

the proposed information collection had

been submitted to OMB for review and

clearance under section 3507 of the PRA

(44 U.S.C. 3507). An agency may not

conduct or sponsor, and a person is not

required to respond to, a collection of

information unless it displays a

currently valid OMB control number.

OMB has now approved the information

collection and has assigned OMB

control number 0910–0025. The

approval expires on October 31, 2000.

Dated: November 27, 1997.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 97–31943 Filed 12–4–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Heart, Lung, and Blood

Institute Special Emphasis Panel (SEP)

meetings:

Name of SEP: Coronary Stent Angioplasty:

Factors Affecting Restenosis (Telephone

Conference Call).

Date: January 6, 1998.

Time: 9:00 a.m.

Place: 6701 Rockledge Drive, Room 7214,

Bethesda, Maryland 20892.

Contact Person: C. James Scheirer, Ph.D.,

Two Rockledge Center, Room 7220, 6701

Rockledge Drive, Bethesda, MD 20892–7924,

(301) 435–0266.

Purpose/Agenda: To review and evaluate

grant applications.

Name of SEP: Specialized Centers of

Research in Acute Lung Injury.

Date: January 7–8, 1998.

Time: 8:00 a.m.

Place: Holiday Inn Chevy Chase, 5520

Wisconsin Avenue, Chevy Chase, Maryland

20815.

Contact Person: Anne P. Clark, Ph.D., Two

Rockledge Center, Room 7186, 6701

Rockledge Drive, Bethesda, MD 20892–7924,

(301) 435–0280.

Purpose/Agenda: To review and evaluate

grant applications.

Name of SEP: Specialized Centers of

Research in Neurobiology of Sleep and Sleep

Apnea.
64392 Federal Register / Vol. 62, No. 234 / Friday, December 5, 1997 / Notices

Date: January 8, 1998.

Time: 8:30 a.m.

Place: Key Bridge Marriott, 1401 Lee

Highway, Arlington, Virginia 22209.

Contact Person: S. Charles Selden, Ph.D.,

Two Rockledge Center, Room 7196, 6701

Rockledge Drive, Bethesda, MD 20892–7924,

(301) 435–0288.

Purpose/Agenda: To review and evaluate

grant applications.

These meetings will be closed in

accordance with the provisions set forth

in secs. 552b(c)(4) and 552b(c)(6), Title

5, U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health.)

Dated: November 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31832 Filed 12–4–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Name of SEP: National Institute on Aging

Special Emphasis Panel, Nutritional Probe of

Aging, (Teleconference).

Date of Meeting: December 18, 1997.

Time of Meeting: 2:00 p.m. to adjournment.

Place of Meeting: National Institute on

Aging, Gateway Building, Room 2C212, 7201

Wisconsin Avenue, Bethesda, MD 20814.

Purpose/Agenda: To review a revised

program project grant application.

Contact Person: Dr. Paul Lenz, Scientific

Review Administrator, Gateway Building,

Room 2C212, National Institutes of Health,

Bethesda, Maryland 20892–9205, (301) 496–

9666.

This meeting will be closed in

accordance with the provisions set forth

in secs. 552b(c)(4) and 552b(c)(6), Title

5, U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program No. 93.866, Aging Research,

National Institutes of Health.)

Dated: December 1, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31831 Filed 12–4–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse

and Alcoholism; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Purpose/Agenda: To review and evaluate

grant applications.

Name of Committee: National Institute on

Alcohol Abuse and Alcoholism Special

Emphasis Panel.

Date of Meeting: December 5, 1997.

Time: 8:00 A.M. to adjournment.

Place of Meeting: Double Tree Hotel, 1750

Rockville Pike, Rockville, MD 20852.

Contact Person: Sean O’Rourke, 6000

Executive Boulevard, Suite 409, Rockville,

MD 20892–7003, 301–443–2861.

The meeting will be closed in

accordance with the provisions set forth

in secs. 552b(c)(4) and 552b(c)(6), Title

5, U.S.C. The proposal and discussions

could reveal confidential trade secrets

or commercial property such as

patentable material, and personal

information concerning individuals

associated with the proposal, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

This notice is being published less

than 15 days prior to the meeting due

to the urgent need to meet timing

limitations imposed by the review and

funding cycle.

(Catalog of Federal Domestic Assistance,

Program Nos. 93.271, Alcohol Research

Career Development Awards for Scientists

and Clinicians; 93.272, Alcohol National

Research Service Awards for Research

Training; 93.273, Alcohol Research Programs;

and 93.891, Alcohol Research Center Grants;

National Institutes of Health.)

Dated: November 20, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31833 Filed 12–4–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Division

of Research Grants Special Emphasis

Panel (SEP) meeting:

Purpose/Agenda: To review individual

grant applications.

Name of SEP: Microbiological and

Immunological.

Date: December 10, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 5110

(Telephone Conference).

Contact Person: Dr. Mohindar Poonian,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5110, Bethesda,

Maryland 20892, (301) 435–1168.

This notice is being published less

than 15 days prior to the above meeting

due to the urgent need to meet timing

limitations imposed by the grant review

and funding cycle.

The meeting will be closed in

accordance with the provisions set forth

in secs. 552b(c)(4) and 552b(c)(6), Title

5, U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93,893, National Institutes of Health,

HHS)

Dated: December 1, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31829 Filed 12–4–97; 8:45 am]

BILLING CODE 4140–01–M